Nektar gains after laying out anticipated milestones for 2019

Shares of Nektar Therapeutics (NKTR) are up nearly 10% following the company’s presentation at JPMorgan’s Healthcare Conference. In addition to saying it ended 2018 with cash and equivalents of $1.92B, Nektar laid out its anticipated milestones in 2019. These include: Initiation of new Bristol-Myers (BMY), Nektar registrational trials in renal cell carcinoma, bladder cancer, non-small cell lung cancer, breast cancer, gastric cancer, colorectal cancer, small cell lung cancer and sarcoma; Presentation of data from PIVOT study of NKTR-214+nivo in patients with bladder cancer at ASCO-GU; Presentation of data from Phase 1 dose-escalation phase of REVEAL study of NKTR-214 + NKTR-262 at ASCO-SITC; Potential approval and launch of NKTR-181; Initiate first Phase 1 clinical trial of NKTR-255 in multiple myeloma; Data from first-in-human Phase 1 single-ascending dose clinical trial of NKTR-358 at EULAR 2019; PIVOT data presentations in lung cancer and Eli Lilly (LLY) initiating two new Phase 1b studies of NKTR-358 in two new auto-immune conditions. Shares of are up over 9%, or $3.45, to $40.07 in afternoon trading.
https://thefly.com/landingPageNews.php?id=2845704